Search the Newsreel

Immix Biopharma, Inc. Stock 12‑Month Price Target Cut to $20.44, Implies 102% Upside

Immix Biopharma, Inc. (IMMX) has seen its average 12-month price target adjusted down slightly from $20.56 to $20.44 by 8 analysts. Despite the minor cut, the new target still implies a significant 102% potential upside from its Aug. 10 closing price. The consensus rating …

Morgan Stanley Adjusts PT on Immix Biopharma to $19 From $20, Maintains Overweight Rating

Morgan Stanley has adjusted its price target for Immix Biopharma (IMMX) to $19, down from $20, while maintaining an Overweight rating on the stock. This update comes after the company recently reported its earnings results for the second quarter and six months ended June …

Renaissance Technologies LLC Buys 76,921 Shares of Lyell Immunopharma, Inc. $LYEL

Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH

Renaissance Technologies LLC has acquired a new stake in Theravance Biopharma, Inc. (NASDAQ:TBPH), purchasing 127,916 shares valued at approximately $2.076 million. This makes Renaissance Technologies LLC one of many institutional investors with holdings in TBPH, as they collectively own 99.10% of the company's stock. …

Key facts: ConocoPhillips names CEO; Truist PT $130; Sen. flags windfall

ConocoPhillips has appointed CFO Andy O'Brien as its new CEO, effective September 1, with Ryan Lance becoming executive chairman. Truist raised its price target for ConocoPhillips (COP) to $130 from $115. Senator Elizabeth Warren has accused ConocoPhillips of recording "windfall profits" linked to geopolitical …

Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Theravance Biopharma, Inc. (TBPH) reported its second quarter 2026 financial results, highlighting a significant 15% increase in total revenue year-over-year, reaching $40 million. The company's net loss decreased by 10% to $18 million, or $0.30 per share, demonstrating improved financial performance. Key updates included …

Benitec Biopharma (NASDAQ:BNTC) Share Price Crosses Above 50 Day Moving Average - Time to Sell?

H.C. Wainwright raises Immix Biopharma price target to $25 By Investing.com

H.C. Wainwright has increased its price target for Immix Biopharma (NASDAQ:IMMX) to $25 from $20, reiterating a Buy rating, despite the company posting a wider net loss for Q2 2026 than previously estimated. The firm cited Immix's strong cash position of $234.2 million, providing …

Arbutus Biopharma (NASDAQ:ABUS) Shares Cross Above 200-Day Moving Average - Should You Sell?

Arbutus Biopharma (NASDAQ:ABUS) shares have moved above their 200-day moving average, reaching $4.67 before closing at $4.59. The company's financial performance includes a quarterly EPS of $0.87 and $179.13 million in revenue, while institutional investors collectively hold 43.79% of its shares. Analyst sentiment is …

Cue Biopharma (NASDAQ:CUE) Trading Down 3.8% - Should You Sell?

Cue Biopharma (NASDAQ:CUE) shares dropped 3.8% to $26.10 in midday trading on Monday, with trading volume significantly higher than average. The company's stock is trading well below its 50-day and 200-day moving averages, and analyst sentiment is predominantly "Sell" despite a recent beat on …

Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?

A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc. (NASDAQ:MRNA). The resolution of their global patent infringement litigation over lipid nanoparticle (LNP) delivery technology provided Arbutus with …

H.C. Wainwright raises Immix Biopharma price target to $25

H.C. Wainwright has raised its price target for Immix Biopharma (NASDAQ:IMMX) to $25 from $20, while reiterating a Buy rating, citing an advanced discounted cash flow valuation and consideration of ex-U.S. sales from NXC-201. The firm updated its earnings estimates, now projecting a net …

Jurgi Camblong Sells 8,500 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

Abhimanyu Verma Sells 5,000 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

SOPHiA GENETICS CTO Abhimanyu Verma sold 5,000 shares of the company's stock for $38,000, reducing his total holdings to 182,171 shares. This sale, executed under a Rule 10b5-1 trading plan, follows several other recent insider transactions. Despite the stock trading near its 12-month high, …

ConocoPhillips (COP) Shares Surge 4.6% -- What GF Score of 84 Te

ConocoPhillips (COP) shares surged 4.6% to $123.03, but the stock is considered approximately 6.5% overvalued according to GuruFocus' GF Value™. While COP holds a strong GF Score™ of 84/100, indicating good profitability and growth, its current P/E ratio is significantly above its historical median. …

ConocoPhillips Announces New CEO Amid Leadership Restructure

ConocoPhillips has announced a leadership restructuring with CFO Andy O’Brien succeeding Ryan Lance as President and CEO, effective September 1, 2026. Ryan Lance will transition to executive chair of the board, and Konnie Haynes-Welsh will become Senior Vice President and CFO. This transition comes …

Form 8K Aspire Biopharma Holdings Inc For: 10 August By Investing.com

This article reports on the filing of a Form 8K by Aspire Biopharma Holdings Inc. for August 10. The filing indicates a significant event or change at the company, as per SEC regulations. The content is brief, primarily serving as an announcement of the …

CONOCOPHILLIPS AKTIE: AI-Analysen, Prognose & Kursziel

Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates

Aspire Biopharma Closes Acquisition of FireFish Units Under Asset and Equity Purchase Agreement

Aspire Biopharma has completed its acquisition of specified subsidiaries and assets from FireFish, a move aimed at expanding its business. To facilitate the closing, an escrow agreement was established on August 6, 2026, making the acquisition automatic upon payment. Concurrently, Aspire Biopharma secured $3.0 …

Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations

Theravance Biopharma (NASDAQ:TBPH) reported quarterly earnings per share of $0.07, matching analysts' consensus estimates. The company showed a strong return on equity of 18.84% and a net margin of 104.34%. Analysts currently maintain a "Hold" rating on the stock with a consensus price target …

Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY

Theravance Biopharma reported a Q2 GAAP net loss of USD 5.9 million, a swing from a profit in the prior year, despite an 11% increase in revenue to USD 20.7 million, primarily from the Viatris collaboration. The company also saw reduced R&D and SG&A …

Is Theravance Biopharma Inc (TBPH) Undervalued After Q2 Earnings

Theravance Biopharma Inc (TBPH) released its Q2 2026 earnings, reporting an 11% increase in YUPELRI collaboration revenue to $20.7 million and a 35% reduction in operating expenses. Despite these gains and a solid cash balance, the company faces challenges, including a failed Phase 3 …

ConocoPhillips CEO Ryan Lance retiring, Andy O'Brien to take over

ConocoPhillips announced that Chief Executive Officer Ryan Lance is stepping down after 14 years at the helm, with Chief Financial Officer Andy O'Brien named as his replacement effective September 1. Lance will move into an executive chair role. The announcement came alongside the company's …

Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M

Theravance Biopharma, Inc. (TBPH) announced its Q2 revenue of $20.7 million, falling short of FactSet's estimate of $22.5 million. The company's stock was trading at 16.90 USD, reflecting a slight dip in performance. Theravance Biopharma specializes in developing and commercializing medicines for respiratory and …

Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS

Form 8K Theravance Biopharma Inc For: 10 August By Investing.com

This article announces that Theravance Biopharma Inc. filed a Form 8K on August 10, 2026. The filing is a standard SEC disclosure for significant corporate events. The brief note from Investing.com provides no further details about the content of the 8K.

Quantum BioPharma (QNTM) Advances MS Treatment with FDA Approval Amid High Price-to-Sales Valuation

Theravance's Once-Daily COPD Treatment Posts $70.7M Sales

Hangzhou Jiuyuan Genetic Biopharmaceutical Sets Board Meeting to Approve Interim Results

ConocoPhillips Stock: A Revised Outlook Following Q2 Earnings (Rating Upgrade) (NYSE:COP)

Theravance Bio: Q2 Earnings Snapshot

Theravance Biopharma Inc. (TBPH) reported a second-quarter loss of $5.9 million, or 11 cents per share. Adjusted earnings were 19 cents per share, while the company's revenue of $20.7 million surpassed analyst expectations of $19.8 million. This financial snapshot highlights their performance in the …

Aspire Biopharma Completes Acquisition of Dura Driver Control Systems, a Leading Global Automotive Supplier with a 100+ Year History and $200M+ in 2025 Revenue

Aspire Biopharma has completed its acquisition of Dura Driver Control Systems (DCS), a tier-one automotive supplier, for $30 million in cash. This acquisition is a strategic move to transform Aspire into a diversified, high-revenue enterprise, leveraging DCS's global manufacturing presence, extensive intellectual property, and …

Karyopharm’s Aug. 13 results call will include slides online

Karyopharm Therapeutics (Nasdaq: KPTI) announced it will report its second-quarter 2026 financial results on August 13, 2026, including a conference call and live audio webcast with accompanying slides at 8:00 a.m. ET. The company will discuss results and provide updates, with an archived replay …

Karyopharm to Report Second Quarter 2026 Financial Results on August 13, 2026

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced it will report its second quarter 2026 financial results on Thursday, August 13, 2026. The company will host a conference call and audio webcast at 8:00 a.m. ET on the same day to discuss the results and provide …

ConocoPhillips Picks Its Next CEO With Big Projects Looming

ConocoPhillips has appointed CFO Andy O’Brien as its new CEO, effective September 1, a transition occurring as the company manages significant projects. A key focus for O'Brien will be the $9 billion Willow project in Alaska, which is central to ConocoPhillips' goal of generating …